Simufilam Regulates Mitochondrial Function in HEK293T TSC2 Knockout Cells
4 affiliations
- 1Departments of Neurosurgery and Cellular & Molecular Physiology, Wu Tsai Institute, Yale University School of Medicine, New Haven, CT 06520-8082, USA
- 2Bioinformatics Support Hub, Cushing/Whitney Medical Library, New Haven, CT 06520-8014, USA
- 3Keck MS & Proteomics Resource, Yale School of Medicine, New Haven, CT 06511-6624, USA
- 4Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, CT 06520-8082, USA
Abstract
The small molecule simufilam, also called PTI-125, has been reported to reduce cell overgrowth and seizure activity in a mouse model of tuberous sclerosis complex (TSC). TSC is a multisystem developmental disorder caused by mutations in TSC1 or TSC2, resulting in mTOR complex 1 (mTORC1) hyperactivity and downstream cellular changes that contribute to focal malformations of the developing cortex and abnormal growth throughout the body. Here, to better understand the role of simufilam at the cellular level, we investigated the impact of simufilam on the proteome of TSC2 knockout (KO) HEK293T cells in vitro. We first validated that TSC2 KO cells displayed increased mTORC1 activity and elevated expression of the stress-associated marker ATF4 compared with TSC2 wild-type (WT) cells. Simufilam reduced ATF4 expression but did not attenuate mTORC1 activity. Next, using LC-MS/MS in TSC2 KO cells, we identified 514 differentially abundant proteins following simufilam treatment. Pathway and protein–protein interaction analyses revealed coordinated changes in mitochondrial translation and bioenergetic pathways, including mitochondrial ribosomal proteins and respiratory-chain-associated proteins, as well as pathways related to preribosome biogenesis, rRNA processing, RNA metabolism, and to some extent RHO GTPase-actin signaling, and chromatin/transcriptional regulation. Selected proteins from these pathways, including MRPS30, MRPL43, MRPL16, ALDH1L2, NDUFA6, and RBM19, were further examined by immunoblotting and found to be altered by simufilam treatment. Functionally, simufilam restored mitochondrial membrane potential in TSC2 KO cells. Overall, these findings support a potential mTORC1-independent role for simufilam in attenuating cellular stress and regulating mitochondrial function in TSC.
Related
- ACAN regulates VSMC mitochondrial homeostasis through the YAP1/TAZ pathway and contributes to the onset and progression of aortic dissection
- CST1 Regulates ER-Mitochondrial Mg²⁺ Balance via MAGT1 to Promote Breast Cancer Metabolism and Growth.
- Bis(4-hydroxyphenyl) Sulfone Regulates Sperm Motility, Mitochondrial Activity, and Nitric Oxide Production in Boar Semen.
- The KLF4–SLC25A4 mitochondrial axis regulates ferroptotic vulnerability and sunitinib sensitivity in clear cell renal cell carcinoma
- MIT-001 mitigates vitrification-induced mitochondrial stress and regulates filamentous actin reorganization, enhancing the survival and development of vitrified-warmed bovine blastocysts.
BibTeX
@article{islam2026simufilam,
title = {{Simufilam Regulates Mitochondrial Function in HEK293T TSC2 Knockout Cells}},
author = {Md. Monirul Islam and Aidan M. Sokolov and Lida Luo and Rolando Garcia-Milian and Katherine B Henke and Tukiet T. Lam and Angélique Bordey},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15201864},
url = {https://www.mdpi.com/2073-4409/15/20/1864},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Simufilam Regulates Mitochondrial Function in HEK293T TSC2 Knockout Cells
AU - Md. Monirul Islam
AU - Aidan M. Sokolov
AU - Lida Luo
AU - Rolando Garcia-Milian
AU - Katherine B Henke
AU - Tukiet T. Lam
AU - Angélique Bordey
PY - 2026
DA - 2026/10/14
JO - Cells
DO - 10.3390/cells15201864
UR - https://www.mdpi.com/2073-4409/15/20/1864
AB - The small molecule simufilam, also called PTI-125, has been reported to reduce cell overgrowth and seizure activity in a mouse model of tuberous sclerosis complex (TSC). TSC is a multisystem developmental disorder caused by mutations in TSC1 or TSC2, resulting in mTOR complex 1 (mTORC1) hyperactivity and downstream cellular changes that contribute to focal malformations of the developing cortex and abnormal growth throughout the body. Here, to better understand the role of simufilam at the cellular level, we investigated the impact of simufilam on the proteome of TSC2 knockout (KO) HEK293T cells in vitro. We first validated that TSC2 KO cells displayed increased mTORC1 activity and elevated expression of the stress-associated marker ATF4 compared with TSC2 wild-type (WT) cells. Simufilam reduced ATF4 expression but did not attenuate mTORC1 activity. Next, using LC-MS/MS in TSC2 KO cells, we identified 514 differentially abundant proteins following simufilam treatment. Pathway and protein–protein interaction analyses revealed coordinated changes in mitochondrial translation and bioenergetic pathways, including mitochondrial ribosomal proteins and respiratory-chain-associated proteins, as well as pathways related to preribosome biogenesis, rRNA processing, RNA metabolism, and to some extent RHO GTPase-actin signaling, and chromatin/transcriptional regulation. Selected proteins from these pathways, including MRPS30, MRPL43, MRPL16, ALDH1L2, NDUFA6, and RBM19, were further examined by immunoblotting and found to be altered by simufilam treatment. Functionally, simufilam restored mitochondrial membrane potential in TSC2 KO cells. Overall, these findings support a potential mTORC1-independent role for simufilam in attenuating cellular stress and regulating mitochondrial function in TSC.
SN - 2073-4409
ER -